You have read all your free articles, to continue reading subscribe to read the rest of this content.
The company has announced that all patients have completed treatment with SiPore15 in the STAR Trial Development is well on track and top-line data will be reported in October this year, states the company in their press release. SiPore15 SiPore15 is a first-in-class medical device using speciaAlready a subscriber Login…
Diaprost has announced a publication in the journal of Clinical Cancer Research on PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates. The extensive preclinical study was conducted at Memorial Sloan Kettering Cancer Center Already a subscriber Login You have read all your free…
Three-year data show early response to Novo's Saxenda resulted in improvements in weight loss and cardiometabolic risk factors. Yesterday data from a post hoc analysis of the three-year part of the phase 3a SCALE (Satiety and Clinical Adiposity – Liraglutide Evidence) Obesity and PrediabetesAlready a subscriber Login You have read all your free…
BioInvent’s collaboration partner ThromboGenics initiates Phase II study with the drug candidate THR-317. BioInvent International AB announces today that the company’s collaboration partner ThromboGenics NV reports that the first patients have been enrolled in a study with the drug candidate Already a subscriber Login You have read all your free…
